Optimization of statin regimens for atherosclerotic cardiovascular disease prevention using polygenic risk scores and real-world evidence – DUPLICATED DO NOT ACTIVATE

Using the GERA cohort, we aim to determine the extent to which atherosclerotic cardiovascular disease (ASCVD) polygenic risk score is associated with baseline ASCVD risk and statin-induced ASCVD relative risk reduction. We will also determine the extent to which the association between ASCVD polygenic risk score and statin-induced ASCVD relative risk reduction is modified by statin benefit group, statin type, and statin dose. Lastly, we will develop an algorithm that predicts baseline ASCVD and statin-induced ASCVD relative risk reduction incorporating ASCVD polygenic risk score on top of traditional ASCVD risk prediction tools. The goal is to use these findings to provide a polygenic risk score-guided precision medicine tool for statin treatment decisions.

0